Mortality in neuropsychiatric systemic lupus erythematosus (NPSLE)

Lupus

Volumn 23, Issue 1, 2014, Pages 31-38

  Zirkzee, E J M ^a   Huizinga, T W J ^a   Bollen, E L E M ^a   Van Buchem, M A ^a   Middelkoop, H A M ^a,b   Van Der Wee, N J A ^a,b   Le Cessie, S ^a   Steup Beekman, G M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY   (Netherlands)

Author keywords

neuropsychiatric lupus; NPSLE; prognosis; Standardized mortality ratio (SMR); survival rate

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; AZATHIOPRINE; CYCLOPHOSPHAMIDE; METHYLPREDNISOLONE; PREDNISOLONE;

ACUTE CONFUSION; ADULT; ANTICOAGULANT THERAPY; ARTICLE; CAUSE OF DEATH; CLINICAL ASSESSMENT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEUROPSYCHIATRIC SYSTEMIC LUPUS ERYTHEMATOSUS; PRESCRIPTION; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; STANDARDIZED MORTALITY RATIO; SURVIVAL RATE; SYSTEMIC LUPUS ERYTHEMATOSUS;

NEUROPSYCHIATRIC LUPUS; NPSLE; PROGNOSIS; STANDARDIZED MORTALITY RATIO (SMR); SURVIVAL RATE;

ADOLESCENT; ADULT; CAUSE OF DEATH; FEMALE; HUMANS; LUPUS VASCULITIS, CENTRAL NERVOUS SYSTEM; MALE; NETHERLANDS; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84890518381     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203313512540     Document Type: Article

References (36)

1. Moss KE, Ioannou Y, Sultan SM, Hag I, Isenberg DA. Outcome of a cohort of 300 patients with systemic lupus erythematosus attending a dedicated clinic for over two decades. Ann Rheum Dis. 2002 ; 61: 409-413
2. Reveille JD, Bartolucci A, Alarcón GS. Prognosis in systemic lupus erythematosus. Negative impact of increasing age at onset, black race, and thrombocytopenia, as well as causes of death. Arthritis Rheum. 1990 ; 33: 37-48
3. Urowitz MB, Gladman DD, Abu-Shakra M, Farewell VT. Mortality studies in systemic lupus erythematosus. Results from a single center. III. Improved survival over 24 years. J Rheumatol. 1997 ; 24: 1061-1065
4. Yurkovich M, Vostretsova K, Chen W, Aviña-Zubieta JA. Overall and cause-specific mortality in patients with systemic lupus erythematosus: A meta-analysis of observational studies. Arthritis Care Res (Hoboken). 2013. doi: 10.1002/acr.22173 [Epub ahead of print].
5. Bernatsky S, Boivin JF, Joseph L, et al. Mortality in systemic lupus erythematosus. Arthritis Rheum. 2006 ; 54: 2550-2557
6. Nossent J, Cikes N, Kiss E, et al. Current causes of death in systemic lupus erythematosus in Europe, 2000-2004: Relation to disease activity and damage accrual. Lupus. 2007 ; 16: 309-317
7. Alarcón GS, McGwin G, Bastian HM, et al. Systemic lupus erythematosus in three ethnic groups. VII [correction of VIII]. Predictors of early mortality in the LUMINA cohort. LUMINA Study Group. Arthritis Rheum. 2001 ; 45: 191-202
8. Abu-Shakra M, Urowitz MB, Gladman DD, Gough J. Mortality studies in systemic lupus erythematosus. Results from a single center. II. Predictor variables for mortality. J Rheumatol. 1995 ; 22: 1265-1270
9. Ginzler EM, Diamond HS, Weiner M, et al. A multicenter study of outcome in systemic lupus erythematosus. I. Entry variables as predictors of prognosis. Arthritis Rheum. 1982 ; 25: 601-611
10. Chambers SA, Allen E, Rahman A, Isenberg D. Damage and mortality in a group of British patients with systemic lupus erythematosus followed up for over 10 years. Rheumatology (Oxford). 2009 ; 48: 673-675
11. Lopez R, Davidson JE, Beeby MD, Egger PJ, Isenberg DA. Lupus disease activity and the risk of subsequent organ damage and mortality in a large lupus cohort. Rheumatology (Oxford). 2012 ; 51: 491-498
12. Mak A, Cheung MW, Chiew HJ, Liu Y, Ho RC. Global trend of survival and damage of systemic lupus erythematosus: Meta-analysis and meta-regression of observational studies from the 1950s to 2000s. Semin Arthritis Rheum. 2012 ; 41: 830-839
13. Funauchi M, Shimadzu H, Tamaki C, et al. Survival study by organ disorders in 306 Japanese patients with systemic lupus erythematosus: Results from a single center. Rheumatol Int. 2007 ; 27: 243-249
14. Urowitz MB, Gladman DD. Evolving spectrum of mortality and morbidity in SLE. Lupus. 1999 ; 8: 253-255
15. Faurschou M, Dreyer L, Kamper AL, Starklint H, Jacobsen S. Long-term mortality and renal outcome in a cohort of 100 patients with lupus nephritis. Arthritis Care Res (Hoboken). 2010 ; 62: 873-880
16. Yap DY, Tang CS, Ma MK, Lam MF, Chan TM. Survival analysis and causes of mortality in patients with lupus nephritis. Nephrol Dial Transplant. 2012 ; 27: 3248-3254
17. Jönsen A, Bengtsson AA, Nived O, Ryberg B, Sturfelt G. Outcome of neuropsychiatric systemic lupus erythematosus within a defined Swedish population: Increased morbidity but low mortality. Rheumatology (Oxford). 2002 ; 41: 1308-1312
18. Mikdashi J, Handwerger B. Predictors of neuropsychiatric damage in systemic lupus erythematosus: Data from the Maryland lupus cohort. Rheumatology (Oxford). 2004 ; 43: 1555-1560
19. Tokano Y, Morimoto S, Amano H, et al. The relationship between initial clinical manifestation and long-term prognosis of patients with systemic lupus erythematosus. Mod Rheumatol. 2005 ; 15: 275-282
20. Bernatsky S, Clarke A, Gladman DD, et al. Mortality related to cerebrovascular disease in systemic lupus erythematosus. Lupus. 2006 ; 15: 835-839
21. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997 ; 40: 1725-1725
22. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982 ; 25: 1271-1277
23. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 1999; 42: 599-608.
24. Zirkzee EJ, Steup-Beekman GM, van der Mast RC, et al. Prospective study of clinical phenotypes in neuropsychiatric systemic lupus erythematosus; multidisciplinary approach to diagnosis and therapy. J Rheumatol. 2012 ; 39: 2118-2126
25. Steup-Beekman GM, Zirkzee EJ, Cohen D, et al. Neuropsychiatric manifestations in patients with systemic lupus erythematosus: Epidemiology and radiology pointing to an immune-mediated cause. Ann Rheum Dis. 2013 ; 72: ii76 - ii79
26. Statistics Netherlands 2012, statline.cbd.nl/statweb/ (accessed 1 September 2012).
27. Therneau TM, Grambsch PM Modeling survival data: Extending the Cox model. New York: Springer-Verlag New York Inc ; 2012: 261-287.
28. Galli L, Spagnuolo V, Salpietro S, et al. Mortality of HIV-infected patients with or without cancer: Comparison with the general population in Italy. Antivir Ther. 2012 ; 17: 447-458
29. Elhai M, Meune C, Avouac J, Kahan A, Allanore Y. Trends in mortality in patients with systemic sclerosis over 40 years: A systematic review and meta-analysis of cohort studies. Rheumatology (Oxford). 2012 ; 51: 1017-1026
30. Sumelahti ML, Hakama M, Elovaara I, Pukkala E. Causes of death among patients with multiple sclerosis. Mult Scler. 2010 ; 16: 1437-1442
31. Christiansen P, Bjerre K, Ejlertsen B, et al. Mortality rates among early-stage hormone receptor-positive breast cancer patients: A population-based cohort study in Denmark. J Natl Cancer Inst. 2011 ; 103: 1363-1372
32. Bertsias GK, Ioannidis JP, Aringer M, et al. EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: Report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis. 2010 ; 69: 2074-2082
33. Aude YW, Mehta JL. Nonplatelet-mediated effects of aspirin. Drugs Today (Barc). 2002 ; 38: 501-507
34. Cohen D, Nabuurs RJ, Steup-Beekman GM, et al. Nationwide autopsy study links complement to thromboischemia in neurolupus (submitted for publication).
35. Cyrus T, Sung S, Zhao L, Funk CD, Tang S, Praticò D. Effect of low-dose aspirin on vascular inflammation, plaque stability, and atherogenesis in low-density lipoprotein receptor-deficient mice. Circulation. 2002 ; 106: 1282-1287
36. McQuaid KR, Laine L. Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials. Am J Med. 2006 ; 119: 624-638